Moderna Reports Positive Results for mRNA Flu Vaccines in Clinical Trials

Reuters

Oct 20

Moderna Inc. has announced that new data regarding two of its investigational influenza vaccine candidates will be presented at IDWeek 2025, scheduled for October 19-22, 2025, in Atlanta, GA.

Moderna jumped 7% on the news.

Among the presentations is an interim assessment from a Phase 1/2 clinical study of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza in adults aged 18 years and older.

The presented data indicate that mRNA-1018 was well-tolerated across all dose levels with no safety concerns identified and demonstrated a rapid and persistent immune response. Three weeks after the second dose, 97.8% of participants achieved immune responses at or above levels considered protective from influenza, with 70.6% maintaining seroprotective titers six months after the second dose. Additional presentations will cover investigational vaccines for cytomegalovirus, RSV, and genital herpes. The results will be presented during scheduled sessions at the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1087698) on October 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576075236"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576075236\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576075236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 23:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576075236","market":"fut","top_or_hot":-1,"title":"Moderna Reports Positive Results for mRNA Flu Vaccines in Clinical Trials","media":"Reuters","content":"<html><head></head><body><p>Moderna Inc. has announced that new data regarding two of its investigational influenza vaccine candidates will be presented at IDWeek 2025, scheduled for October 19-22, 2025, in Atlanta, GA. </p><p>Moderna jumped 7% on the news.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2d207008d71f99aa6ea08465aff368cd\" tg-width=\"894\" tg-height=\"833\"/></p><p>Among the presentations is an interim assessment from a Phase 1/2 clinical study of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza in adults aged 18 years and older. </p><p>The presented data indicate that mRNA-1018 was well-tolerated across all dose levels with no safety concerns identified and demonstrated a rapid and persistent immune response. Three weeks after the second dose, 97.8% of participants achieved immune responses at or above levels considered protective from influenza, with 70.6% maintaining seroprotective titers six months after the second dose. Additional presentations will cover investigational vaccines for cytomegalovirus, RSV, and genital herpes. The results will be presented during scheduled sessions at the conference.</p><p><em>Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1087698) on October 19, 2025, and is solely responsible for the information contained therein.</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Reports Positive Results for mRNA Flu Vaccines in Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Reports Positive Results for mRNA Flu Vaccines in Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 23:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Moderna Inc. has announced that new data regarding two of its investigational influenza vaccine candidates will be presented at IDWeek 2025, scheduled for October 19-22, 2025, in Atlanta, GA. </p><p>Moderna jumped 7% on the news.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2d207008d71f99aa6ea08465aff368cd\" tg-width=\"894\" tg-height=\"833\"/></p><p>Among the presentations is an interim assessment from a Phase 1/2 clinical study of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza in adults aged 18 years and older. </p><p>The presented data indicate that mRNA-1018 was well-tolerated across all dose levels with no safety concerns identified and demonstrated a rapid and persistent immune response. Three weeks after the second dose, 97.8% of participants achieved immune responses at or above levels considered protective from influenza, with 70.6% maintaining seroprotective titers six months after the second dose. Additional presentations will cover investigational vaccines for cytomegalovirus, RSV, and genital herpes. The results will be presented during scheduled sessions at the conference.</p><p><em>Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1087698) on October 19, 2025, and is solely responsible for the information contained therein.</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDLf3FTB:1","article_id":"2576075236","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576075236","pubTimestamp":1760974286,"columns":[{"name":"Earnings Express","id":26,"label_key":"express"},{"name":"Data Report","id":30,"label_key":"dataReport"},{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Moderna Inc. has announced that new data regarding two of its investigational influenza vaccine candidates will be presented at IDWeek 2025, scheduled for October 19-22, 2025, in Atlanta, GA. Among the presentations is an interim assessment from a Phase 1/2 clinical study of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza in adults aged 18 years and older. The presented data indicate that mRNA-1018 was well-tolerated across all dose levels with no safety concerns identified and demonstrated a rapid and persistent immune response. Three weeks after the second dose, 97.8% of participants achieved immune responses at or above levels considered protective from influenza, with 70.6% maintaining seroprotective titers six months after the second dose. Additional presentations will cover investigational vaccines for cytomegalovirus, RSV, and genital herpes. The results will be presented during scheduled sessions at the conference.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓","MRNA":"Moderna, Inc.","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4551":"寇图资本持仓","BK4501":"段永平概念"},"translate_title":"Moderna报告mRNA流感疫苗在临床试验中取得积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna Inc. has announced that new data regarding two of its investigational influenza vaccine candidates will be presented at IDWeek 2025, scheduled for October 19-22, 2025, in Atlanta, GA. Moderna jumped 7% on the news.Among the presentations is an interim assessment from a Phase 1/2 clinical study of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza in adults aged 18 years and older. The presented data indicate that mRNA-1018 was well-tolerated across all dose levels with no safety concerns identified and demonstrated a rapid and persistent immune response. Three weeks after the second dose, 97.8% of participants achieved immune responses at or above levels considered protective from influenza, with 70.6% maintaining seroprotective titers six months after the second dose. Additional presentations will cover investigational vaccines for cytomegalovirus, RSV, and genital herpes. The results will be presented during scheduled sessions at the conference.Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1087698) on October 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,dataReport,movement,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}